Clinical Trial

An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma

Study acronym: GLOW-FISH
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients. The aim of this imaging study is to determine a safe and effective dose of anti-GD2-800CW for intra-operative detection of neuroblastoma using NIR fluorescence.
Trial Details
NCT Number NCT07399821
Lead Sponsor Princess Maxima Center for Pediatric Oncology
Conditions Neuroblastoma
Enrollment 22 participants
Start Date 2025-11-05
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-10